Drug Trial Radar · NCT00704665
Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma
Last checked: Nov 20, 2026Latest source record: Jun 25, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
231
Actual
Start
Dec 1998
Primary completion
Dec 2001
Study completion Dec 2001
Sponsor
- Lead sponsor
- University of Medicine and Dentistry of New JerseyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of California, Los Angeles; Boston University; University of Chicago; UConn Health; Johns Hopkins University; University of Pittsburgh; Medical University of South Carolina; Stanford University; Georgetown University; University of California, San Diego; Wayne State University; University of Colorado, Denver; Medical College of Wisconsin
- First posted
- Jun 25, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Relaxin is a naturally occurring protein prduced by the ovary or placenta in pregnancy. It has ani-fibrotic properties. Previous studies have shown that relaxin is safe at concentrations upto 60 times higher than achieved in pregnancy. Study is designed to see if skin improvement and improvement in functional ability can be achieved.
Conditions
- Systemic Sclerosis
Interventions
RelaxinDrug
10 ug/kg/day or 25 ug/kg/day
RelaxinDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- MRSSTime frame: baseline, weeks 4,12, and 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.